200 related articles for article (PubMed ID: 24113515)
1. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells.
Kim SS; Rait A; Rubab F; Rao AK; Kiritsy MC; Pirollo KF; Wang S; Weiner LM; Chang EH
Mol Ther; 2014 Feb; 22(2):278-291. PubMed ID: 24113515
[TBL] [Abstract][Full Text] [Related]
2. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
[TBL] [Abstract][Full Text] [Related]
3. Radiotheranostic Targeting Cancer Stem Cells in Human Colorectal Cancer Xenografts.
She X; Qin S; Jing B; Jin X; Sun X; Lan X; An R
Mol Imaging Biol; 2020 Aug; 22(4):1043-1053. PubMed ID: 32125599
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
5. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
6. miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells.
Wang J; Lei ZJ; Guo Y; Wang T; Qin ZY; Xiao HL; Fan LL; Chen DF; Bian XW; Liu J; Wang B
Oncotarget; 2015 Nov; 6(35):37852-70. PubMed ID: 26497997
[TBL] [Abstract][Full Text] [Related]
7. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
9. Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70.
Hyun SY; Le HT; Min HY; Pei H; Lim Y; Song I; Nguyen YTK; Hong S; Han BW; Lee HY
Theranostics; 2021; 11(6):2932-2952. PubMed ID: 33456581
[No Abstract] [Full Text] [Related]
10. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model.
Gomez-Cabrero A; Wrasidlo W; Reisfeld RA
PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113
[TBL] [Abstract][Full Text] [Related]
11. Can nanomedicines kill cancer stem cells?
Zhao Y; Alakhova DY; Kabanov AV
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1763-83. PubMed ID: 24120657
[TBL] [Abstract][Full Text] [Related]
12. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
14. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Xu L; Tang WH; Huang CC; Alexander W; Xiang LM; Pirollo KF; Rait A; Chang EH
Mol Med; 2001 Oct; 7(10):723-34. PubMed ID: 11713371
[TBL] [Abstract][Full Text] [Related]
15. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
16. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
17. The Delivery of a Wnt Pathway Inhibitor Toward CSCs Requires Stable Liposome Encapsulation and Delayed Drug Release in Tumor Tissues.
Li C; Liang Y; Cao J; Zhang N; Wei X; Tu M; Xu F; Xu Y
Mol Ther; 2019 Sep; 27(9):1558-1567. PubMed ID: 31350188
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine-mediated cancer stem cell therapy.
Shen S; Xia JX; Wang J
Biomaterials; 2016 Jan; 74():1-18. PubMed ID: 26433488
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
